IMF Videos Search Content For Healthcare Professional (70) Healthcare Provider (70) Series - Any - About the IMF (2) ASCO/EHA (70) ASH (102) Ask Dr. Durie (150) Black Swan Research Initiative (7) Community Workshops (5) Emerging Therapies (18) Facebook Live (21) Health Equity (14) IMF History (3) IMWG (12) Inspirational (15) Living Well with Myeloma (33) Myeloma in a Minute (20) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (11) Q&A (21) Recent News and Developments (5) Treatments (3) Trending Searches in Myeloma (4) Topics Clinical Trials (49) Financial Considerations (1) Frontline Therapy (16) Health Equity (2) Lab & Imaging Tests (1) Mental & Emotional Health (1) Myeloma in the News (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (31) Research Updates (51) Symptom Management (4) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (16) High-Risk Myeloma (14) High-risk Smoldering Myeloma (9) Late Relapse (4–6 Lines of Therapy) (29) MGUS (5) Newly Diagnosed (Pre-Treatment or First Treatment) (20) Smoldering Myeloma (7) Types of Therapy Immunomodulatory drugs (IMiDs) (22) Immunotherapies (CAR T; BiTE, etc.) (30) Monoclonal antibodies (20) Proteasome inhibitors (20) Stem cell transplant (10) Steroids (17) Supportive Care (8) Year Published 2026 (1) 2025 (14) 2024 (17) 2023 (17) 2022 (1) 2021 (3) 2020 (3) 2019 (2) 2018 (2) 2017 (5) 2015 (5) Trusted Voices Dr. Joseph Mikhael (2) Dr. María-Victoria Mateos (1) Dr. S. Vincent Rajkumar (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Maintenance Therapy with Carfilzomib, Pomalidomide, and Dex (KPd) in High-Risk Myeloma Patients June 30, 2023 ASCO/EHA Updated Results of BCMA/CD19 Dual-targeting Fast CAR-T GC012F Dual-targeting CAR-T in RRMM June 30, 2023 ASCO/EHA Safety and Efficacy of elranatamab in RRMM & Prior BCMA Therapies: Analysis from MagnetisMM Studies June 29, 2023 ASCO/EHA CARTITUDE-4: Cilta-cel vs standard of care PVd or DPd in lenalidomide-refractory multiple myeloma June 26, 2023 ASCO/EHA Durability of Responses with Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Myeloma June 26, 2023 ASCO/EHA Comparing Health Related Quality of Life in TCE RRMM: Ide-cel vs. Standard Regimens June 26, 2023 ASCO/EHA DREAMM-9: Belantamab mafodotin + Standard Care in Newly Diagnosed Multiple Myeloma June 22, 2023 ASCO/EHA GPRC5D-Targeted CAR T-Cell Therapy for RRMM: Phase 1 Study Outcomes of BMS-986393 (CC-95266) June 20, 2023 ASCO/EHA IDE-CEL vs Standard Regimens for High-Risk Multiple Myeloma: KARMMA-3 Analysis June 19, 2023 ASCO/EHA RedirecTT-1 Study: Dual Targeting of BCMA and GPRC5D in RRMM Patients with Teclistamab and Talquetamab June 19, 2023 ASCO/EHA LINKER-MM1 Trial: Evaluating Linvoseltamab (REGN5458) in Patients with Relapsed or Refractory Multiple Myeloma June 14, 2023 ASCO/EHA Disparities in multiple myeloma: A global perspective on drug toxicity trends June 13, 2023 ASCO/EHA Load More
